On the record
Ipamorelin is banned in sport, never FDA-approved, and detectable in urine — here is what the studies actually measured.
A receipts-first digest that leads with the anti-doping paper trail: how growth-hormone secretagogues get caught, the ~2-hour half-life that the testing windows hang on, and the lone human trial that missed.
The short version (no spin)
Most of what's online about Ipamorelin is sales copy. Here's the plain version. Ipamorelin is a lab-made peptide — a short chain of five amino acids — that tells your pituitary gland to release a pulse of growth hormone (the body's natural "grow and repair" signal). It copies ghrelin, the hormone that also makes you hungry, by hitting the same docking site on cells (the ghrelin receptor). Its one party trick: it raises growth hormone while barely touching stress hormones like cortisol. That's why researchers found it interesting in the 1990s.
Here's what the marketing skips. It was never approved as a medicine anywhere. The single proper human trial — for slow bowels after surgery — failed. It is banned in sport and drug labs can find it in urine. People online report better sleep, faster recovery, more appetite, and a warm flush after injecting — but that's talk, not proof. What people actually report, including the downsides, is on the effects page.
Lead with the part nobody selling it wants to talk about: detection
Ipamorelin is on the World Anti-Doping Agency (WADA) Prohibited List, category S2 (peptide hormones and growth factors), banned at all times — in and out of competition. This is not a gray area. Analytical chemists have determined growth-hormone-releasing-peptide metabolites in human urine and built the screening methods that anti-doping labs use to catch the whole class [7]. Translation: it is findable, and the methods to find it are published.
The paper trail goes further. When anti-doping researchers tore apart seized black-market "growth-promoting" products, they identified Gly-Ipamorelin — ipamorelin with an extra glycine bolted onto one end — as a designer analogue, confirmed by custom synthesis and high-resolution mass spectrometry [9]. The structure-activity work mapped which positions in the shared peptide core drive binding to the ghrelin receptor (GHS-R1a), and confirmed active forms turning up in urine after dosing [8]. The detection science is a moving target, but the target is being hit.
If you want the kinetics that make those urine windows tick, that's the whole point of how long does ipamorelin stay in your system.
What ipamorelin actually is (the one-paragraph version)
Ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; CAS 170851-70-4) is a synthetic pentapeptide — five linked amino acids — that selectively activates GHS-R1a, the receptor that the hunger hormone ghrelin normally binds. Activate that receptor on the pituitary and you get a discrete pulse of growth hormone (GH). It was engineered from an older peptide, GHRP-1, by stripping out a two-amino-acid chunk, and two of its building blocks are "D-form" mirror-image amino acids that make it harder for the body's enzymes to chew up [1].
The headline pharmacology — the reason it earned the label "first selective growth hormone secretagogue" — is what it doesn't do. In its founding 1998 characterization it released GH potently in rat pituitary cells, anaesthetised rats, and conscious pigs (pig ED50 = 2.3 nmol/kg, edging out GHRP-6 at 3.9 nmol/kg), yet did not push ACTH or cortisol above baseline even at doses more than 200 times its GH-releasing dose [1]. Earlier peptides in this family raised cortisol and prolactin; ipamorelin mostly didn't. That selectivity is its entire identity.
The honest scorecard: strong in rodents, thin and negative in humans
Rodent data is real and reproducible. Subcutaneous ipamorelin at 18, 90, and 450 micrograms/day (split three times daily for 15 days) dose-dependently sped up longitudinal bone growth in adult female rats — from 42 to 52 micrometers/day at the top dose — without measurably changing systemic IGF-1 [4]. The freshest in-vivo work, a 2024 ferret study, found intraperitoneal ipamorelin (1-3 mg/kg) blunted chemotherapy-driven weight loss by about 24% in the delayed phase, though it did nothing for nausea [5].
Human data is where the story deflates. The only published Phase 2 randomized trial — 114 adults given 0.03 mg/kg IV twice daily after bowel surgery — missed its primary endpoint: median time to a tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, which sounds better until you see p=0.15, i.e. not statistically significant [3]. There is no Phase 3 trial and no approved use anywhere. Whether it is is ipamorelin fda approved has a short, blunt answer: no.
Want the Ipamorelin research in full, the reported Ipamorelin effects, or the Ipamorelin references — it's all sourced here, and nothing on this site is for sale.